These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20528402)

  • 1. Are Medicare plans complying with CMS regulation?
    Cohen J; Young B; Rochon S; Faden L
    Expert Rev Pharmacoecon Outcomes Res; 2008 Apr; 8(2):133-9. PubMed ID: 20528402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing Medicare prescription drug plans in four states: balancing cost and access.
    Heaton E; Carino T; Dix H
    Issue Brief (Commonw Fund); 2006 Aug; 22():1-14. PubMed ID: 16933399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.
    Bowman J; Rousseau A; Silk D; Harrison C
    Health Aff (Millwood); 2006; 25(5):1240-8. PubMed ID: 16966719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
    Thomas CP; Sussman J; ;
    Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
    Sengupta S
    N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
    Davis MM; Patel MS; Halasyamani LK
    J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA.
    Kennedy J; Dipzinski A; Roll J; Coyne J; Blodgett E
    Drug Alcohol Depend; 2011 Apr; 114(2-3):201-6. PubMed ID: 21134724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicaid preferred drug lists' costs to physicians.
    Ketcham JD; Epstein AJ
    Med Care; 2008 Jan; 46(1):9-16. PubMed ID: 18162850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare and Medicaid programs; Medicare-Medicaid coverage data bank requirements: preliminary guidance--HCFA. Notice.
    Fed Regist; 1994 May; 59(89):24167-70. PubMed ID: 10135128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.